Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

• Authors: BLENNOW Ola; SALMANTON-GARCIA Jon; NOWAK Piotr; ITRI Federico; JAAP Van Doesum; LOPEZ-GARCIA Alberto; FARINA Francesca; JAKSIC Ozren; PINCZES Laszlo Imre; BILGIN Yavuz M; FALCES-ROMERO Iker; JIMENEZ Moraima; ORMAZABAL-VELEZ Irati; WEINBERGEROVÁ Barbora; DULERY Remy; STOJANOSKI Zlate; LAHMER Tobias; FERNANDEZ Noemi; HERNANDEZ-RIVAS Jose-angel; PETZER Verena; NICK De Jonge; GLENTHOJ Andreas; CRISTINA De Ramon; BIERNAT Monika M; FRACCHIOLLA Nicola; AUJAYEB Avinash; JENS Van Praet; SCHONLEIN Martin; MENDEZ Gustavo-Adolfo; CATTANEO Chiara; GUIDETTI Anna; SCIUME Mariarita; AMMATUNA Emanuele; CORDOBA Raul; GARCIA-POUTON Nicole; GRAEFE Stefanie; CABIRTA Alba; WOLF Dominik; NORDLANDER Anna; GARCIA-SANZ Ramon; DELIA Mario; CAROLINE Berg Venemyr; BRONES Clara; ROBERTA Di Blasi; ELIZABETH De Kort; MEERS Stef; LAMURE Sylvain; SERRANO Laura; MERELLI Maria; COPPOLA Nicola; BERGANTIM Rui; BESSON Caroline; KOHN Milena; PETITI Jessica; GARCIA-VIDAL Carolina; DARGENIO Michelina; DANION Francois; MACHADO Marina; BAILEN-ALMOROX Rebeca; HOENIGL Martin; DRAGONETTI Giulia; CHAI Louis Yi Ann; KHO Chi Shan; BONANNI Matteo; LIEVIN Raphael; MARCHESI Francesco; CORNELY Oliver A; PAGANO Livio
• Year of publication: 2022
• Type: Article in Periodical
• Magazine / Source: American Journal of Hematology
• MU Faculty or unit: Faculty of Medicine
• web: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26626
• Doi: http://dx.doi.org/10.1002/ajh.26626
• Keywords: omicron SARS-CoV-2 variant; hematological malignancies
• Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.